Use of enoxaparin in end-stage renal disease

Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
Silvia Lai and Bettina Coppola
Kidney Int 84: 433-436; doi:10.1038/ki.2013.163

Additional Info

  • Language:
  • Contains Audio:
  • Content Type:
  • Source:
  • Year:
  • Members Only:

Read 2933 times

Last modified on Friday, 28 March 2014 11:58

Scroll to Top